Clinical trial

S0313 Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, and Radiation…

NCT00070018 · SWOG Cancer Research Network, Other · Completed

Key facts

NCT number NCT00070018
Title S0313 Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, and Radiation Therapy Followed By Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Stage I or Stage II Non-Hodgkin's Lymphoma
Official title Evaluation of CHOP Plus Involved Field Radiotherapy Followed by Yttrium-90 Ibritumomab Tiuxetan for Stages I, IE, and Non-Bulky Stages II and IIE, CD20 Positive, High-Risk Localized, Aggressive Histologies of Non-Hodgkin Lymphoma, Phase II
Lead sponsor SWOG Cancer Research Network, Other
Collaborators National Cancer Institute (NCI) NIH
Status Completed
Phase Phase 2
Study type Interventional
Conditions Lymphoma
Intervention type Biological, Drug, Radiation
Interventions rituximab, Cyclophosphamide, doxorubicin hydrochloride, prednisone, vincristine sulfate, radiation therapy, Yttrium-90 ibritumomab tiuxetan, Indium-111 ibritumomab tiuxetan
Enrollment 46
Start date Feb 1, 2004
Primary completion Nov 1, 2010
Completion Jan 8, 2015
First posted Oct 7, 2003
Last update posted Jan 11, 2022
Countries United States

At a glance

  • 10–99 Study sites
  • Yes Results posted
  • None Linked FDA submissions

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About ClinicalTrials.gov studies

ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.

Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date:

Browse all ClinicalTrials.gov studies